Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenalisib in metastatic triple negative breast cancer
NCT06189209Phase 2Recruiting
- Sponsor
- Rhizen Pharmaceuticals AG
- Start
- Mar 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tenalisib in triple-negative breast cancer (TNBC), sponsored by Rhizen Pharmaceuticals AG. Started Mar 2024; status: recruiting.
02
Drugs
tenalisib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06189209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06189209.